scispace - formally typeset
P

P. Van Schil

Researcher at University of Antwerp

Publications -  167
Citations -  8566

P. Van Schil is an academic researcher from University of Antwerp. The author has contributed to research in topics: Lung cancer & Thoracotomy. The author has an hindex of 32, co-authored 167 publications receiving 6972 citations. Previous affiliations of P. Van Schil include European Organisation for Research and Treatment of Cancer & Vita-Salute San Raffaele University.

Papers
More filters
Journal ArticleDOI

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Peter Goldstraw, +142 more
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
Journal ArticleDOI

Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial

Jörg Ederle, +351 more
- 20 Mar 2010 - 
TL;DR: Completion of long-term follow-up is needed to establish the efficacy of carotid artery stenting compared with endarterectomy, but in the meantime, carotin artery stent should remain the treatment of choice for patients suitable for surgery.
Journal ArticleDOI

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

TL;DR: A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease.
Journal ArticleDOI

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

TL;DR: The ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up for malignant pleural mesothelioma show clear trends in survival and morbidity and recommend a 6-month to 12-monthFollow-up period for diagnosis and treatment.
Journal ArticleDOI

Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

TL;DR: Department of Medical Oncology, Thoracic Group, Gustave-Roussy Villejuif, France; Royal Marsden Hospital, London; Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, UK; Department of Oncologists, University of Turin, San Luigi Hospital, Orbassano, Italy.